NASDAQ 100 Pre-Market Performance: The NASDAQ 100 Pre-Market Indicator is up 380.3 points to 25,440.11, with a total pre-market volume of 219,886,694 shares traded.
Active Stocks Overview: InflaRx N.V. (IFRX) and Greenidge Generation Holdings Inc. (GREE) are among the most active stocks, with IFRX trading at $2.01 and GREE at $2.02, both showing positive movements.
Earnings Reports and Forecasts: IFRX and Innate Pharma S.A. (IPHA) are scheduled to release earnings reports soon, with IPHA showing a significant forecasted increase in earnings per share compared to last year.
Stock Recommendations: Several stocks, including NVIDIA Corporation (NVDA) and IonQ, Inc. (IONQ), are currently in the "buy range" according to Zacks, indicating positive market sentiment.
Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 12.67 USD with a low forecast of 6.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 12.67 USD with a low forecast of 6.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 1.030
Low
6.00
Averages
12.67
High
24.00
Current: 1.030
Low
6.00
Averages
12.67
High
24.00
Leerink
Outperform -> Market Perform
downgrade
$2
2025-12-03
Reason
Leerink
Price Target
$2
AI Analysis
2025-12-03
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded InflaRx to Market Perform from Outperform with a $2 price target.
Leerink
Joseph Schwartz
Outperform -> Market Perform
downgrade
$5 -> $2
2025-12-03
Reason
Leerink
Joseph Schwartz
Price Target
$5 -> $2
2025-12-03
downgrade
Outperform -> Market Perform
Reason
Leerink analyst Joseph Schwartz downgraded InflaRx to Market Perform from Outperform with a price target of $2, down from $5. InflaRx delivered unexpectedly positive Phase 2a data for INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria, with the HS results looking compelling enough to justify a Phase 2b trial, the analyst tells investors in a research note. Despite management's view that its EUR 44.4M cash balance can fund operations into 2027, further financing appears likely and could be notably dilutive at the current valuation.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IFRX
Unlock Now
Raymond James
Ryan Deschner
Outperform
maintain
$2 -> $9
2025-11-11
Reason
Raymond James
Ryan Deschner
Price Target
$2 -> $9
2025-11-11
maintain
Outperform
Reason
Raymond James analyst Ryan Deschner raised the firm's price target on InflaRx to $9 from $2 and keeps an Outperform rating on the shares. Inflarx reported "strong" early efficacy and safety data from their oral C5aR inhibitor INF904 in Hidradenitis Suppurative patients in a Phase 2a autoimmune disease basket study, the analyst tells investors in a research note. The response of HS patients at 4 weeks is very positive, given competitive levels of HiSCR response were seen at 4 weeks, further increasing for at least four more weeks post-treatment, and Raymond James believes there is ample room for an oral drug with a novel mechanism in the HS market.
Oppenheimer
Andreas Argyrides
Outperform
maintain
$3 -> $7
2025-11-11
Reason
Oppenheimer
Andreas Argyrides
Price Target
$3 -> $7
2025-11-11
maintain
Outperform
Reason
Oppenheimer analyst Andreas Argyrides raised the firm's price target on InflaRx to $7 from $3 and keeps an Outperform rating on the shares following positive results from the Phase 2a basket study of INF904 in hidradenitis suppurative and chronic spontaneous urticaria. The firm sees INF904 emerging as a best-in-class oral therapy with favorable safety and a superior PK/PD profile vs. avacopan. The robust results derisk INF904's profile, warranting further development in both indications, Oppenheimer adds.
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
